IL1B and uveitis: The same team studied 19 Behçet’s uveitis and reported that anti-IL-1 therapy improved retinal vasculitis lesions and decreased uveitis flares (from 200/100 patients/year before treatment to 48.87/100 patients/year during the 12 months of the study).